NASDAQ:MRUS 30 December 2025 - 8 May 2026

Genmab A/S dropped roughly 10% in Copenhagen Friday, after the Danish biotech posted a steep first-quarter profit decline. Higher costs from its Merus deal and stepped-up R&D spending canceled out a healthy bump in revenue. Around midday CEST, shares were quoted at 1,586.25 Danish crowns, down 9.8%, Cboe Europe data showed on MarketScreener. Investors are watching this quarter closely, since it’s among the first to reflect what Genmab’s spending looks like as it shifts away from its traditional royalty model. Last year, Genmab struck an $8 billion deal to acquire Merus, a Dutch cancer drugmaker, picking up late-stage candidate petosemtamab for head-and-neck cancer. The move signals Genmab’s effort to lean more heavily on its own product sales instead of depending so much on its partners.

NEW YORK, December 30, 2025, 11:14 ET — Regular session Merus N.V. shares were halted on Tuesday after Nasdaq said the final merger step in Denmark’s Genmab’s $97-a-share cash acquisition closed before the market open, leaving the stock set for suspension on Dec. 31. Merus last traded around $90 late Monday, about 7% below its prior close, according to market data. NASDAQ Trader